{
    "2020-01-18": [
        [
            {
                "time": "2023-10-05",
                "original_text": "‘This is nuts’ — one strategist explains why he just reduced risk by selling Apple, Microsoft and more",
                "features": {
                    "keywords": [
                        "reduced risk",
                        "selling",
                        "Apple",
                        "Microsoft"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "If You Had Bought Johnson & Johnson (NYSE:JNJ) Shares Five Years Ago You'd Have Made 46%",
                "features": {
                    "keywords": [
                        "Bought",
                        "Johnson & Johnson",
                        "Shares",
                        "Five Years Ago",
                        "46%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Judge cuts $8bn J&J Risperdal verdict to $6.8m",
                "features": {
                    "keywords": [
                        "Judge",
                        "cuts",
                        "$8bn",
                        "J&J",
                        "Risperdal",
                        "verdict",
                        "$6.8m"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Drugmakers slash prices to be eligible for China's bulk-buy program",
                "features": {
                    "keywords": [
                        "Drugmakers",
                        "slash",
                        "prices",
                        "eligible",
                        "China",
                        "bulk-buy",
                        "program"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}